Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Photocure
Company

Photocure

Tracked across 5 events · 32 articles · First seen May 07, 2026 · Last active Aug 14, 2026

Sentiment
51
Attention
4
Events
5
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (5)
4 70
Business
Photocure Q1 2026 Earnings Report
Impact: Photocure reported strong Q1 2026 revenues and adjusted EBITDA, with significant milestone payments for Cevira approvals. The company expects continued product revenue growth and EBITDA margin expansion, driven by increased adoption of blue-light cystoscopy and strategic partnerships.
May 07, 2026 · 6 articles
3 70
Business
Photocure, Artera partner bladder cancer AI
Impact: Photocure is a key partner in this research initiative, providing its BLC registry data and expertise in bladder cancer diagnostics to develop and validate the ArteraAI Bladder Test. This collaboration enhances Photocure's position in precision medicine.
Jun 08, 2026 · 8 articles
2 15
Business
Photocure Q2 2026 results and acquisition
Impact: Photocure reported Q2 2026 results with revenue growth, raised guidance, and advanced strategic initiatives including the acquisition of Vesica Health and collaboration with Artera. The company is well-positioned for future growth.
Jul 29, 2026 · 6 articles
2 20
Tech
Photocure BLC cost-neutrality study published
Photocure ASA announced the publication of a retrospective cohort study in JU Open Plus evaluating the economic implications of blue light cystoscopy (BLC) versus white light cystoscopy (WLC) using Hexvix/Cysview in a real-world setting. The…
Impact: Photocure announced the study publication, which supports the cost-effectiveness of its product Hexvix/Cysview, potentially strengthening its market position.
Aug 11, 2026 · 6 articles
4 80
Regulatory
FDA Proposes Reclassifying Blue Light Cystoscopy Systems
On August 14, 2026, the U.S. United States — Food and Drug Administration (FDA) published a proposed order in the Federal Register to reclassify cystoscopic systems intended as an aid for the detection of bladder…
Impact: Photocure is the primary beneficiary, as the reclassification could expand the U.S. market for its Cysview product and related equipment, potentially increasing sales and market share.
Aug 14, 2026 · 6 articles
Key Actions (2)
100 United States — Food and Drug Administration proposed reclassification PhotocureFDA Proposes Reclassifying...
80 Photocure published studyPhotocure BLC...
Relationships (2)
Dan Schneider ↔ Photocure
Dan Schneider ceo ↔ Photocure Dan Schneider is the President and Chief Executive Officer of Photocure, leading
ERGEN INTELLIGENCE
Track Photocure live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.